Biomind Labs Inc. (BMND.NE)
Biomind Labs Inc.
Building Ceibo Of. 002
Camino Saravia s/n 91.000, Pando
Canelones
Uruguay
https://www.biomindlabs.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 5
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Alejandro Antalich | CEO & Director | 94.67k | N/D | 1974 |
| Mr. Oscar Alejandro Leon | CFO & Director | N/D | N/D | 1960 |
| Ms. Paola Diaz Dellavalle Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
| Mr. Juan Presa | Chief Legal Officer | N/D | N/D | N/D |
| Ms. Magdalena Alvarez M.A. | Head of Communication | N/D | N/D | N/D |
| Mr. Martin Daners | Head of Quality Assurance & Regulatory Affairs | N/D | N/D | N/D |
Descripción
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
Gestión corporativa
La calificación ISS Governance QuickScore de Biomind Labs Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
